Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Skin Cancer

Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper

J Geriatr Oncol.

Bastiaannet E, Battisti N, Loh KP, de Glas N, Soto-Perez-de-Celis E, Baldini C, Kapiteijn E, Lichtman S

doi: 10.1016/j.jgo.2018.06.009.

Central Nervous System Tumors

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Eur J Cancer

Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L, Kudura K, Gérard CL, Levesque MP, Michielin O, Dummer R, Cheng PF, Mangana J

doi: 10.1016/j.ejca.2021.07.028

Central Nervous System Tumors

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Eur J Cancer

Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L, Kudura K, Gérard CL, Levesque MP, Michielin O, Dummer R, Cheng PF, Mangana J

doi: 10.1016/j.ejca.2021.07.028

Skin Cancer

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review

JAMA Oncol.

Dummer R, Ascierto PA, Nathan P, Robert C, Schadendorf D

doi: 10.1001/jamaoncol.2020.4401.

SPECIAL REPORT

Further Publications

Adjuvant Targeted Therapy in BRAF-Mutated Melanoma

Skin Cancer

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma

Melanoma Res.

Seremet T, Planken S, Schwarze JK, Jansen Y, Vandeweerd L, van den Begin R, Tsechelidis I, Lienard D, Del Marmol V, Neyns B

doi: 10.1097/

RECOMMENDED

Further Publications

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

Eur J Cancer.

Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Dalle S, Falandry C, Péron J

doi: 10.1016/j.ejca.2019.08.027.

Genitourinary Cancer

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Anticancer Res.

Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M

doi: 10.21873/anticanres.11480

Lung, Respiratory and Thoracic Cancer

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

JAMA Oncol.

Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R

doi: 10.1001/

Related content

Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review

Adjuvant Targeted Therapy in BRAF-Mutated Melanoma

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis